4.7 Article

Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life

期刊

COMMUNICATIONS BIOLOGY
卷 5, 期 1, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/s42003-022-03787-x

关键词

-

资金

  1. Division of Head, Neck and Reconstructive Surgery at Oslo University Hospital
  2. Dr. Jon S Larsens Foundation
  3. Futura Fund for Scientific Medical Research
  4. Aase Bye and Trygve J.B. Hoff Ophthalmological Fund
  5. Norwegian Association of Blind and Partially Sighted
  6. South-Eastern Norway Regional Health Authority [2018052, 2019084]
  7. Research Council of Norway [274993, 287927, 314909]

向作者/读者索取更多资源

The analysis of clinically approved antibody-based therapeutics reveals that different structural designs have distinct biophysical properties affecting FcRn binding, intracellular transport, and plasma half-life. Understanding the impact of different features of antibody-based therapeutics on FcRn binding and transport is crucial for optimizing cellular sorting and plasma half-life. This study compares the FcRn engagement of IgG1 Fc fragment to clinically relevant IgGs and receptor domain Fc fusions, binding to VEGF or TNF-alpha, and provides insights into their intracellular accumulation, plasma half-life, and cellular transportation.
Analysis of clinically approved antibody-based therapeutics reveals different structural designs, such as full-length IgG1 or Fc-fusions, entail distinct biophysical properties that affect FcRn binding, intracellular transport and plasma half-life. Antibody-based therapeutics (ABTs) are used to treat a range of diseases. Most ABTs are either full-length IgG1 antibodies or fusions between for instance antigen (Ag)-binding receptor domains and the IgG1 Fc fragment. Interestingly, their plasma half-life varies considerably, which may relate to how they engage the neonatal Fc receptor (FcRn). As such, there is a need for an in-depth understanding of how different features of ABTs affect FcRn-binding and transport behavior. Here, we report on how FcRn-engagement of the IgG1 Fc fragment compare to clinically relevant IgGs and receptor domain Fc fusions, binding to VEGF or TNF-alpha. The results reveal FcRn-dependent intracellular accumulation of the Fc, which is in line with shorter plasma half-life than that of full-length IgG1 in human FcRn-expressing mice. Receptor domain fusion to the Fc increases its half-life, but not to the extent of IgG1. This is mirrored by a reduced cellular recycling capacity of the Fc-fusions. In addition, binding of cognate Ag to ABTs show that complexes of similar size undergo cellular transport at different rates, which could be explained by the biophysical properties of each ABT. Thus, the study provides knowledge that should guide tailoring of ABTs regarding optimal cellular sorting and plasma half-life.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据